mTORC2 Deficiency Alters the Metabolic Profile of Conventional Dendritic Cells
In myeloid dendritic cells (DC), deletion of the mechanistic target of rapamycin complex 2 (TORC2) results in an augmented pro-inflammatory phenotype and T cell stimulatory activity; however, the underlying mechanism has not been resolved. Here, we demonstrate that mouse bone marrow-derived TORC2-deficient myeloid DC (TORC2−/− DC) utilize an altered metabolic program, characterized by enhanced baseline glycolytic function compared to wild-type WT control (Ctrl) DC, increased dependence on glycolytic ATP production, elevated lipid content and higher viability following stimulation with LPS. In addition, TORC2−/− DC display an increased spare respiratory capacity (SRC) compared to WT Ctrl DC; this metabolic phenotype corresponds with increased mitochondrial mass and mean mitochondrial DNA copy number, and failure of TORC2−/− DC mitochondria to depolarize following LPS stimulation. Our data suggest that the enhanced metabolic activity of TORC2−/− DC may be due to compensatory TORC1 pathway activity, namely increased expression of multiple genes upstream of Akt/TORC1 activity, including the integrin alpha IIb, protein tyrosine kinase 2/focal adhesion kinase, IL-7R and Janus kinase 1(JAK1), and the activation of downstream targets of TORC1, including p70S6K, eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and CD36 (fatty acid translocase). These enhanced TORC1 pathway activities may culminate in increased expression of the nuclear receptor peroxisome proliferator-activated receptor γ (Pparγ) that regulates fatty acid storage, and the transcription factor sterol regulatory element-binding transcription factor 1 (Srebf1). Taken together, our data suggest that TORC2 may function to restrain TORC1-driven metabolic activity and mitochondrial regulation in myeloid DC.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1016/j.cell.2006.01.016
- https://doi.org//10.1038/cr.2007.64
- https://doi.org//10.1038/nri2546
- https://doi.org//10.1016/j.immuni.2010.09.002
- https://doi.org//10.1126/scisignal.267pe24
- https://doi.org//10.1016/j.cub.2004.06.054
- https://doi.org//10.1016/j.cell.2012.03.017
- https://doi.org//10.1182/blood-2002-11-3370
- https://doi.org//10.1182/blood-2008-02-137430
- https://doi.org//10.1016/j.immuni.2008.08.012
- https://doi.org//10.1182/blood-2004-10-3932
- https://doi.org//10.4049/jimmunol.178.11.7018
- https://doi.org//10.4049/jimmunol.1402551
- https://doi.org//10.1080/2162402X.2016.1146841
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (9)
CATEGORIES
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity